---
title: "BioHarvest Sciences (BHST) begins trading on Tel Aviv Stock Exchange in dual listing"
url: "https://aibio.space/news/bioharvest-sciences-bhst-begins-trading-tel-aviv-stock-exchange-dual/"
event_date: "2026-09-03"
date_published: "2026-11-08"
description: "BioHarvest Sciences (Nasdaq: BHST) said on September 3, 2026 that it would dual list its 22,667,842 outstanding common shares on the Tel Aviv Stock Exchange. A September 15 report says trading began there on September 8."
---

# BioHarvest Sciences (BHST) begins trading on Tel Aviv Stock Exchange in dual listing

BioHarvest Sciences Inc. (Nasdaq: BHST) announced on September 3, 2026 that it would register its common shares for trading on the Tel Aviv Stock Exchange, a dual listing alongside its Nasdaq listing. The release said trading in Tel Aviv was expected to begin on September 8, 2026. A later [material change report dated September 15, 2026](https://www.sec.gov/Archives/edgar/data/1723464/000172346426000054/bhsc_ex991.htm) records that the shares began trading on the TASE on September 8, 2026.

Why is this important: The registration covers shares already outstanding, shares reserved under the equity incentive plan and warrant shares, and the release names no new offering. The company's interim statements for the six months to June 30, 2026 carry a going concern note. Cash and cash equivalents fell from $23,025 thousand at December 31, 2025 to $15,211 thousand at June 30, 2026.

Dr Zaki Rakib, whom the September release calls chief executive, is named as chairman of the board in the March 31, 2026 annual report, where Ilan Sobel is listed as chief executive officer. The August 11, 2026 interim statements carry Rakib's signature as chief executive officer and chairman of the board. In our view, a company whose filings give conflicting titles for its chief executive should settle that before holders judge how it will handle its funding gap. The listing widens access to the shares. It does not change the finances.

## What the registration covers

The company asked the Tel Aviv Stock Exchange to register all 22,667,842 outstanding common shares, which have no par value. It also requested registration of up to 4,516,021 common shares for future issue under its equity incentive plan. Of those, 2,564,876 are options and 269,521 are restricted share units outstanding, and 1,681,624 remain available for future grants.

The request also covers 610,742 common shares issuable on exercise of 610,742 warrants granted to investors. Any future issue of additional shares will need TASE approval, the release says. The common shares stay listed on the Nasdaq Capital Market under BHST.

Dr Zaki Rakib framed the step this way: "As an Israeli-founded company with global ambitions, we believe a dual listing on the Tel Aviv Stock Exchange alongside Nasdaq is a natural step". The release presents the listing as a way to broaden access to the shares and to strengthen the company's connection with the Israeli investment community.

## The company's business and its latest interim figures

The release describes BioHarvest as a leader in Botanical Synthesis, a platform the company says grows plant-based compounds without growing the underlying plant. It names two business verticals: a contract development and manufacturing organization serving customers who want novel plant-based compounds, and a creator of nutraceutical and wellness products. The release also warns that for the contract business there is no assurance of additional future contracts, and that increased revenue is not necessarily an increase in net income.

The company's unaudited interim statements for the three and six months ended June 30, 2026 report cash and cash equivalents of $15,211 thousand, against $23,025 thousand at December 31, 2025. Revenue for the six months was $17,344 thousand. The accumulated deficit reached $113,909 thousand, against $107,553 thousand at year end.

Loans stood at $2,662 thousand at June 30, 2026, all classed as current. The notes describe investor loans at 5%, 10% and 12% interest, with 24-month terms. The same interim notes say the company has not yet achieved sustained cash-flow profitability, and that these factors raise substantial doubt about its ability to continue as a going concern. The notes also say the company completed a voluntary delisting of its shares from the Canadian Securities Exchange in February 2025 and continues to be listed on the Nasdaq Stock Market.

## What comes next

The release said the shares would begin trading on the TASE on September 8, 2026, under the English symbol BHST and a Hebrew symbol. It also says all future EDGAR filings will be filed through the MAGNA Disclosure System at the same time.

The material change report, dated September 15, 2026, confirms that trading began on September 8, the date the release gave.

Sources

- https://www.sec.gov/Archives/edgar/data/1723464/000172346426000054/bhsc_ex991.htm
- https://www.biospace.com/press-releases/bioharvest-sciences-registers-for-dual-listing-on-the-tel-aviv-stock-exchange-tase
- https://www.sec.gov/Archives/edgar/data/1723464/000172346426000044/bhsc_ex991.htm
- https://www.sec.gov/Archives/edgar/data/1723464/000137647426000257/bhst-20251231_40f.htm
